US International Development Finance Corporation has committed a long-term loan of up to USD 20 million to Panacea Biotec. The funds will help expand the manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix, aimed at meeting future demand from UN agencies and public health organisations.